Physician profile
Thomas King
NPI 1497005268
$2,206.64
in general payments reported to CMS, 2019-2025
20 companies · $620 in 2025
The $620 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $344 · 2022: $516 · 2023: $528 · 2024: $198 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,346.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $575.41 | 2021-2025 | |
| Indivior INC. | $384.68 | 2021-2025 | Sublocade |
| Corcept Therapeutics | $214.04 | 2024-2025 | Korlym |
| Braeburn INC. | $173.63 | 2024-2025 | Brixadi |
| Biohaven Pharmaceuticals, INC. | $160.82 | 2021 | |
| Collegium Pharmaceutical, INC. | $134.16 | 2021-2024 | Belbuca |
| Otsuka America Pharmaceutical, INC. | $125.45 | 2021-2023 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Gilead Sciences, INC. | $97.56 | 2023 | Epclusa |
| Biohaven Pharmaceutical Holding Company Ltd. | $58.43 | 2022 | |
| Pfizer INC. | $46.51 | 2023 | |
| Forte Bio-Pharma LLC | $34.09 | 2023 | Prolate, Nalocet |
| Biotissue Holdings INC. | $34.01 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $27.96 | 2023 | Zilretta, Exparel, Iovera |
| Vertex Pharmaceuticals Incorporated | $27.10 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.77 | 2025 | Caplyta |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $19.38 | 2025 | Hetlioz, Fanapt |
| Janssen Pharmaceuticals, INC | $18.91 | 2025 | Invega Sustenna |
| Idorsia Pharmaceuticals US INC | $18.10 | 2023 | Quviviq |
| Novo Nordisk INC | $16.51 | 2023 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $14.12 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.